Related Experiment Video
Updated: Sep 23, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.5K
Arterial hypertension - clinical trials update 2022
Felix Götzinger1, Michael Kunz2, Lucas Lauder2
1Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital Saarland, Saarland University, 66424, Homburg, Germany. felix.goetzinger@uks.eu.
Summary
Recent hypertension clinical trials offer new insights into treatment targets for the elderly and resistant hypertension management. Research also covers early combination therapy, drug safety, and renal denervation
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Hypertension is a leading global cardiovascular risk factor, contributing to significant morbidity and mortality.
- Many patients fail to reach target blood pressure levels despite current treatments, highlighting the need for ongoing research.
- Advances in understanding and managing hypertension are crucial for public health.
Purpose of the Study:
- To review and synthesize key clinical trials in hypertension published in 2021-2022.
- To discuss emerging trends and evidence in hypertension management.
- To provide an update on novel therapeutic strategies and drug safety.
Main Methods:
- Systematic review and discussion of recent (2021-2022) hypertension clinical trials.
- Analysis of studies focusing on treatment targets, lifestyle interventions, and pharmacotherapy.
- Inclusion of data on drug safety and procedural interventions like renal denervation.
Main Results:
- New data on treatment targets for elderly patients and the impact of salt intake and lifestyle on resistant hypertension.
- Evidence supporting early antihypertensive combination therapy and the use of specific drug classes in resistant cases.
- Insights into the carcinogenicity of antihypertensive drugs, acetaminophen's effect on blood pressure, and the role of renal denervation.
Conclusions:
- Continued research is vital for improving hypertension control and patient outcomes.
- Novel therapeutic approaches and a deeper understanding of risk factors are emerging.
- Evidence supports refined strategies for managing resistant hypertension and reassessing drug safety profiles.
Related Concept Videos
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
64
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
64
01:29Hypertension II: Pathophysiology
108
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
108
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
76
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
76
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
266
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
266
01:18Hypertension and Regulation of Blood Pressure
3.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.1K
01:11Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K